Guggenheim Capital LLC Chemo Centryx, Inc. Transaction History

Guggenheim Capital LLC

$14 Billion
Q3 2024

Shares

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 14, 2022	SELL	$22.17 - $51.8 $148,760 - $347,578	-6,710 Reduced 15.7%	36,026 $1.86 Million
Q2 2022 Aug 15, 2022	SELL	$15.36 - $27.51 $48,384 - $86,656	-3,150 Reduced 6.86%	42,736 $1.06 Million
Q1 2022 May 16, 2022	BUY	$22.22 - $39.12 $122,854 - $216,294	5,529 Added 13.7%	45,886 $1.15 Million
Q4 2021 Feb 14, 2022	SELL	$18.38 - $40.5 $316,577 - $697,572	-17,224 Reduced 29.91%	40,357 $1.47 Million
Q3 2021 Nov 15, 2021	SELL	$13.18 - $19.83 $107,561 - $161,832	-8,161 Reduced 12.41%	57,581 $985,000
Q2 2021 Aug 13, 2021	BUY	$9.59 - $50.88 $304,731 - $1.62 Million	31,776 Added 93.55%	65,742 $880,000
Q1 2021 May 13, 2021	SELL	$49.53 - $68.4 $4,259 - $5,882	-86 Reduced 0.25%	33,966 $1.74 Million
Q4 2020 Feb 16, 2021	BUY	$47.25 - $65.16 $1.61 Million - $2.22 Million	34,052 New	34,052 $2.11 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.